vs
Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
DYNEX CAPITAL INC is the larger business by last-quarter revenue ($43.5M vs $34.1M, roughly 1.3× Karyopharm Therapeutics Inc.). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs 11.6%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs 1.4%).
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
DX vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $34.1M |
| Net Profit | — | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | — | -52.4% |
| Net Margin | — | -299.9% |
| Revenue YoY | 531.3% | 11.6% |
| Net Profit YoY | — | -232.0% |
| EPS (diluted) | $1.59 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | $34.1M | ||
| Q3 25 | $30.6M | $44.0M | ||
| Q2 25 | $23.1M | $37.9M | ||
| Q1 25 | $17.1M | $30.0M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | — | $38.8M | ||
| Q2 24 | — | $42.8M | ||
| Q1 24 | $-3.2M | $33.1M |
| Q4 25 | — | $-102.2M | ||
| Q3 25 | $150.4M | $-33.1M | ||
| Q2 25 | $-13.6M | $-37.3M | ||
| Q1 25 | $-3.1M | $-23.5M | ||
| Q4 24 | — | $-30.8M | ||
| Q3 24 | — | $-32.1M | ||
| Q2 24 | — | $23.8M | ||
| Q1 24 | $40.1M | $-37.4M |
| Q4 25 | — | -52.4% | ||
| Q3 25 | — | -34.6% | ||
| Q2 25 | — | -64.3% | ||
| Q1 25 | — | -110.8% | ||
| Q4 24 | — | -102.4% | ||
| Q3 24 | — | -67.8% | ||
| Q2 24 | — | -65.7% | ||
| Q1 24 | — | -101.9% |
| Q4 25 | — | -299.9% | ||
| Q3 25 | 491.3% | -75.2% | ||
| Q2 25 | -58.8% | -98.2% | ||
| Q1 25 | -18.0% | -78.2% | ||
| Q4 24 | — | -100.8% | ||
| Q3 24 | — | -82.7% | ||
| Q2 24 | — | 55.6% | ||
| Q1 24 | -1256.8% | -112.8% |
| Q4 25 | $1.59 | $-7.02 | ||
| Q3 25 | $1.08 | $-3.82 | ||
| Q2 25 | $-0.14 | $-4.32 | ||
| Q1 25 | $-0.06 | $-2.77 | ||
| Q4 24 | — | $-2.33 | ||
| Q3 24 | — | $-3.85 | ||
| Q2 24 | — | $-2.97 | ||
| Q1 24 | $0.64 | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $531.0M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.5B | $-292.9M |
| Total Assets | $17.3B | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.0M | $60.5M | ||
| Q3 25 | $491.0M | $37.7M | ||
| Q2 25 | $387.5M | $38.7M | ||
| Q1 25 | $327.4M | $38.8M | ||
| Q4 24 | — | $62.5M | ||
| Q3 24 | — | $72.8M | ||
| Q2 24 | — | $84.8M | ||
| Q1 24 | $295.7M | $30.6M |
| Q4 25 | $2.5B | $-292.9M | ||
| Q3 25 | $2.0B | $-269.3M | ||
| Q2 25 | $1.6B | $-238.9M | ||
| Q1 25 | $1.4B | $-205.9M | ||
| Q4 24 | — | $-186.0M | ||
| Q3 24 | — | $-159.6M | ||
| Q2 24 | — | $-132.1M | ||
| Q1 24 | $958.5M | $-169.0M |
| Q4 25 | $17.3B | $108.4M | ||
| Q3 25 | $14.2B | $96.2M | ||
| Q2 25 | $11.3B | $104.9M | ||
| Q1 25 | $9.0B | $127.7M | ||
| Q4 24 | — | $164.4M | ||
| Q3 24 | — | $189.5M | ||
| Q2 24 | — | $214.0M | ||
| Q1 24 | $6.3B | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.8M | $-11.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.8M | $-11.8M | ||
| Q3 25 | $68.3M | $-5.9M | ||
| Q2 25 | $31.9M | $-18.7M | ||
| Q1 25 | $6.4M | $-39.0M | ||
| Q4 24 | — | $-25.8M | ||
| Q3 24 | — | $-19.5M | ||
| Q2 24 | — | $-38.5M | ||
| Q1 24 | $-17.1M | $-43.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-43.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -84.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -132.6% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× | ||
| Q1 24 | -0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DX
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
